유전체 분석 1세대 마크로젠, 해외 매출 62% 달성…AI 대전환 속도

Macrogen demonstrates how genomics expertise fuels evolution to AI-driven digital healthcare, with 2025 profitability and 62% international revenue validating the business model's viability in global markets. The Global Genome Center and North America entry (CLIA/CAP certified) establish the data-AI infrastructure needed to scale from diagnostic services into integrated health platforms. This exemplifies how Korean biotech firms can leverage specialized genomics capabilities to become competitive players in the global medical AI ecosystem.